[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555499":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":23,"locations":29,"responsibleParty":167,"collaborators":22,"id":169,"slug":22,"hasResults":170,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":170,"sex":176,"minAge":177,"maxAge":178,"enrollmentInfo":179,"targetDuration":22,"studyType":182,"phases":183,"briefSummary":185,"conditions":186,"keywords":22,"overallStatus":32,"whyStopped":22,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":198},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"EGPA\u002FHES Cohort: Benralizumab","EXPERIMENTAL","Participants with greater than or equal to (\\>=) 35 kg weight will receive benralizumab dose-1 and participants with less than (\\\u003C) 35 kg weight will receive benralizumab dose-2 as SC injection Q4W during the 52-week treatment period. All participants who complete the 52-week treatment period will be offered the opportunity to continue into an extension period.",[13],"Drug: Benralizumab",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Benralizumab","Benralizumab will be administered as SC injection on Q4W.",[9],[21],"FASENRA",null,[24],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[30,43,53,61,70,80,89,97,106,115,124,133,142,150,159],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":22},"Research Site","RECRUITING","Aurora","Colorado","80045","United States",{"type":38,"coordinates":39},"Point",[40,41],-104.83192,39.72943,{"lat":41,"lon":40},{"facility":31,"status":44,"city":45,"state":46,"zip":47,"country":36,"cosmosGeoPoint":48,"geoPoint":52,"contacts":22},"NOT_YET_RECRUITING","Cincinnati","Ohio","45229",{"type":38,"coordinates":49},[50,51],-84.51439,39.12711,{"lat":51,"lon":50},{"facility":31,"status":32,"city":54,"state":46,"zip":55,"country":36,"cosmosGeoPoint":56,"geoPoint":60,"contacts":22},"Highland Hills","44106-2624",{"type":38,"coordinates":57},[58,59],-81.51901,41.44839,{"lat":59,"lon":58},{"facility":31,"status":32,"city":62,"state":22,"zip":63,"country":64,"cosmosGeoPoint":65,"geoPoint":69,"contacts":22},"São Paulo","01232-010","Brazil",{"type":38,"coordinates":66},[67,68],-46.63611,-23.5475,{"lat":68,"lon":67},{"facility":31,"status":32,"city":71,"state":72,"zip":73,"country":74,"cosmosGeoPoint":75,"geoPoint":79,"contacts":22},"Toronto","Ontario","M5G1X8","Canada",{"type":38,"coordinates":76},[77,78],-79.39864,43.70643,{"lat":78,"lon":77},{"facility":31,"status":44,"city":81,"state":22,"zip":82,"country":83,"cosmosGeoPoint":84,"geoPoint":88,"contacts":22},"Lille","59037","France",{"type":38,"coordinates":85},[86,87],3.05512,50.63391,{"lat":87,"lon":86},{"facility":31,"status":44,"city":90,"state":22,"zip":91,"country":83,"cosmosGeoPoint":92,"geoPoint":96,"contacts":22},"Montpellier","34295",{"type":38,"coordinates":93},[94,95],3.87635,43.61093,{"lat":95,"lon":94},{"facility":31,"status":44,"city":98,"state":22,"zip":99,"country":100,"cosmosGeoPoint":101,"geoPoint":105,"contacts":22},"Ahmedabad","380052","India",{"type":38,"coordinates":102},[103,104],72.58727,23.02579,{"lat":104,"lon":103},{"facility":31,"status":44,"city":107,"state":22,"zip":108,"country":109,"cosmosGeoPoint":110,"geoPoint":114,"contacts":22},"Petah Tikva","49202","Israel",{"type":38,"coordinates":111},[112,113],34.88747,32.08707,{"lat":113,"lon":112},{"facility":31,"status":32,"city":116,"state":22,"zip":117,"country":118,"cosmosGeoPoint":119,"geoPoint":123,"contacts":22},"Guadalajara","44620","Mexico",{"type":38,"coordinates":120},[121,122],-103.34749,20.67738,{"lat":122,"lon":121},{"facility":31,"status":44,"city":125,"state":22,"zip":126,"country":127,"cosmosGeoPoint":128,"geoPoint":132,"contacts":22},"Rotterdam","3015 GD","Netherlands",{"type":38,"coordinates":129},[130,131],4.47917,51.9225,{"lat":131,"lon":130},{"facility":31,"status":44,"city":134,"state":22,"zip":135,"country":136,"cosmosGeoPoint":137,"geoPoint":141,"contacts":22},"Kielce","25-734","Poland",{"type":38,"coordinates":138},[139,140],20.62752,50.87033,{"lat":140,"lon":139},{"facility":31,"status":44,"city":143,"state":22,"zip":144,"country":136,"cosmosGeoPoint":145,"geoPoint":149,"contacts":22},"Warsaw","04-730",{"type":38,"coordinates":146},[147,148],21.01178,52.22977,{"lat":148,"lon":147},{"facility":31,"status":32,"city":151,"state":22,"zip":152,"country":153,"cosmosGeoPoint":154,"geoPoint":158,"contacts":22},"Altındağ","06230","Turkey (Türkiye)",{"type":38,"coordinates":155},[156,157],37.70324,37.09145,{"lat":157,"lon":156},{"facility":31,"status":32,"city":160,"state":22,"zip":161,"country":153,"cosmosGeoPoint":162,"geoPoint":166,"contacts":22},"Istanbul","34093",{"type":38,"coordinates":163},[164,165],28.94966,41.01384,{"lat":165,"lon":164},{"type":168,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100555499",false,"NCT06512883","A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases","Phase 3, Open-label Trial to Evaluate Safety, Pharmacokinetics, and Efficacy of Benralizumab in Children With Eosinophilic Diseases (CLIPS)","CLIPS","Inclusion Criteria:\n\nAll Cohorts:\n\n* Male or female participants must be aged 6 to \\\u003C 18 years of age at the time of signing the assent form and their caregiver signing the informed consent form.\n* Body weight greater than (\\>=) 15 kilograms (kg).\n\nEGPA Cohort:\n\n* Therapy with corticosteroids: The prescribed dose of oral corticosteroids (OCS) (greater than \\[\\>\\] 0.1 milligrams per kilogram per day (mg\u002Fkg\u002Fday), max dose of 50 milligrams per day (mg\u002Fday) must be stable (that is, no adjustment of the dose) for at least 4 weeks prior to baseline (Visit 2).\n* Immunosuppressive therapy: If receiving immunosuppressive therapy, the dosage must be stable for at least 4 weeks prior to baseline (Visit 2).\n\nHES Cohort:\n\n* Documented HES diagnosis, defined as history of persistent eosinophilia \\>1500 cells\u002FµL without secondary cause on 2 examinations ≥1 month apart and evidence of eosinophil-mediated organ involvement.\n* Symptomatic active HES, or history of a prior flare, or considered eligible based on disease severity per investigator judgement.\n* AEC ≥1000 cells\u002FµL at screening (Visit 1).\n* Documented negative testing for Fip1-like 1 gene fused with the platelet-derived growth factor receptor alpha gene (FIP1L1-PDGFR) fusion tyrosine kinase gene translocation.\n\nExclusion Criteria:\n\nAll Cohorts:\n\n* Any current malignancy or history of malignancy.\n* History of anaphylaxis to any biologic therapy or vaccine.\n* Known, pre-existing, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological, respiratory, or any other system abnormalities.\n* Previous receipt of benralizumab in an interventional clinical study.\n\nEGPA Cohort:\n\n* Diagnosed with granulomatosis with polyangiitis (previously known as Wegener'granulomatosis) or microscopic polyangiitis.\n* EGPA relapse: any deterioration in EGPA and\u002For organ-threatening EGPA that per Investigator judgement renders participants unstable in their EGPA within 3 months prior to screening (Visit 1) and through first administration of IP at baseline (Visit 2).\n* Life-threatening EGPA: imminently life-threatening EGPA disease within 3 months prior to screening (Visit 1) and through first administration of IP at baseline (Visit 2), as per Investigator judgement.\n\nHES Cohort:\n\n* Life-threatening HES or HES complications, as judged by the investigator.\n* Hypereosinophilia of unknown significance (HE-US).\n* Diagnosis of systemic mastocytosis.","ALL","6 Years","17 Years",{"count":180,"type":181},14,"ESTIMATED","INTERVENTIONAL",[184],"PHASE3","The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.",[187,188],"Eosinophilic Granulomatosis With Polyangiitis (EGPA)","Hypereosinophilia Syndrome (HES)","2026-06-29",{"date":191,"type":192},"2026-06-30","ACTUAL",{"date":194,"type":192},"2025-04-17",{"date":196,"type":181},"2029-05-14",{"name":5,"class":6},15]